Moreover, the genetic profile revealed mutation concordance between the CTCs and primary tumour with regard to the activating variant c.1799 T > A in the BRAF gene responsible for the pathogenic p.Val600Glu (V600E, rs113488022) missense mutation. Here, BRAF is linked to neoplasm.